Avelumab

Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development

Retrieved on: 
화요일, 3월 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Carcinoma, Alkermes, Erasmus University Rotterdam, Cetuximab, Patient, SVP, ImClone Systems, Biostatistics, Merck, Epidemiology, Management, University, MBA, Merck Group, Limited partnership, MPH, Therapy, International school, PPD, Eli Lilly and Company, Marketing, Avelumab, Daiichi Sankyo

“We are very pleased to welcome Jeltje and Rita to our talented team.

Key Points: 
  • “We are very pleased to welcome Jeltje and Rita to our talented team.
  • Dr. Schulten received her medical degree from Erasmus University, Rotterdam, Netherlands and her MBA from the International School of Management RSM, Rotterdam, Netherlands.
  • Dr. Rita Dalal is a trained physician with extensive and diverse clinical research experience including in solid tumor oncology.
  • Previously, Dr. Dalal held clinical research scientist positions with Merck Sharp & Dohme Corp. and Eli Lilly and Company.

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Retrieved on: 
목요일, 1월 4, 2024
IO, Merck Group, ASX, Autoimmune disease, Immune system, Death, Bladder cancer, Carcinoma, Hope, IMM, PD-L1, Avelumab, Research, Cancer, Transitional cell carcinoma, Patient, Safety, Transitional epithelium

SYDNEY, AUSTRALIA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the first patient has been enrolled and safely dosed in the INSIGHT-005 Phase I trial. The investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate eftilagimod alpha (“efti”) in combination with BAVENCIO® (avelumab) in up to 30 patients with metastatic urothelial carcinoma.

Key Points: 
  • The investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate eftilagimod alpha (“efti”) in combination with BAVENCIO® (avelumab) in up to 30 patients with metastatic urothelial carcinoma.
  • Encouragingly, responses were achieved even in cancer patients with low and negative PD-L1 expression, who typically would not be expected to respond to anti-PD-(L)1 therapy.
  • Daniel Pink, as part of the investigator-initiated INSIGHT platform for studies investigating efti in different combination treatments and routes of administration.
  • For 2023, it was estimated there would be 82,290 new cases of bladder cancer and 16,710 deaths in the US alone.1

Pfizer Completes Acquisition of Seagen

Retrieved on: 
목요일, 12월 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NYSE, Research, Policy, Acquisition, PFE, Spacecraft, LLP, Avelumab, Investment, ADC, Brentuximab vedotin, Antibody-drug conjugate, Protein engineering, Sullivan & Cromwell, Science, Centerview Partners, Oliver Cromwell, AACR, Cancer, Death, Financial toxicity, Communication, Federal Trade Commission, Growth, Guggenheim Partners, Inc., Arnold & Porter, Conjugation, Education, Pharmaceutical industry, Fine chemical, Pfizer, Seagen

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.
  • Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.
  • With the addition of Seagen, Pfizer’s Oncology pipeline has doubled in size with 60 programs spanning multiple modalities, including ADCs, small molecules, bispecifics and other immunotherapies.
  • “This is a great day for Pfizer, and, more importantly, for people living with cancer, as we bring together the game-changing science and top talent of Seagen and Pfizer to form a leading Oncology organization,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

Retrieved on: 
화요일, 12월 12, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Webcast, Pfizer, Research, Acquisition, NYSE, Policy, PFE, Hart–Scott–Rodino Antitrust Improvements Act, Avelumab, Patient, Science, Vaccine, Cancer, Communication, Federal Trade Commission, EST, Inc., AACR, Education, Pharmaceutical industry, Seagen

Pfizer and Seagen have now received all required regulatory approvals to complete the acquisition.

Key Points: 
  • Pfizer and Seagen have now received all required regulatory approvals to complete the acquisition.
  • Pfizer expects to close the acquisition of Seagen on December 14, 2023, subject to the satisfaction of other customary closing conditions.
  • Pfizer also announces changes in its commercial organization to incorporate Seagen and improve focus, speed and quality of execution.
  • During the call Pfizer will discuss the Seagen acquisition, new commercial organization, and provide full-year 2024 financial guidance.

G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
수요일, 11월 1, 2023
Survival, Patient, Research, SCLC, Patent, Event, Food, PIN, Pivotal, Thrombocytopenia, Public expenditure, SG, RESEARCH, Telephone, Organization, GAAP, Wind, Total revenue, Acquisition, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, TNBC, Update, Clinical trial, Security, Webcast, Interim, Avelumab, Guideline, Anemia, G1 Therapeutics, Net, Therapy, Hospital, PARK, OS, Regenerative Medicine Advanced Therapy, Neutropenia, ASCO, Acceleration, Shanda, Pharmaceutical industry, Video game, Fine chemical, Cryptocurrency, Simcere Pharmaceutical, G1

Recognized $10.8 Million in Net COSELA Revenue: G1 recognized total revenues of $12.3 million for the third quarter of 2023.

Key Points: 
  • Recognized $10.8 Million in Net COSELA Revenue: G1 recognized total revenues of $12.3 million for the third quarter of 2023.
  • Vial volume grew 3% over the second quarter of 2023 despite the impact of an ongoing platinum-based chemotherapy shortage.
  • Ended the Third Quarter of 2023 with Cash, Cash Equivalents, and Marketable Securities of $94.4 Million.
  • Operating expenses for the third quarter of 2023 were $28.7 million, compared to $45.1 million for the third quarter of 2022.

EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023

Retrieved on: 
월요일, 10월 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Annual general meeting, Cancer, Health care, Food, UC, MCC, Abstract, IAP, NSCLC, Apoptosis, European Society for Medical Oncology, Cisplatin, OS, Ageing, Safety, Lung cancer, US Foods, Angela Merkel, Patient, FDA, ESMO, Chemoradiotherapy, Skin cancer, Phase, Booth, Merck, LA, Neck, Maintenance, Bladder cancer, Merck Group, Lung, Head, Merck Serono, Avelumab, Progression-free survival, MET, SCCHN, Pharmaceutical industry, Nightclub

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.

Key Points: 
  • EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.
  • Additional presentations and activities at ESMO highlight the company’s efforts to improve the lives of people with cancer.
  • New analyses and real-world evidence to be presented at ESMO reinforce the role of the JAVELIN Bladder regimen in this setting.
  • In September 2023, the accelerated approval in the US was converted into full approval for use of BAVENCIO for the treatment of metastatic MCC.

Merck to Present Latest Research from Oncology Portfolio at ESMO 2023

Retrieved on: 
월요일, 10월 16, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Annual general meeting, Cancer, Cetuximab, UC, Food, MCC, Biomarker, Abstract, IAP, NSCLC, Apoptosis, European Society for Medical Oncology, Cisplatin, OS, Ageing, Safety, Lung cancer, US Foods, Angela Merkel, Patient, FDA, ESMO, Chemoradiotherapy, Skin cancer, Phase, Booth, LA, Neck, Maintenance, Bladder cancer, Lung, Head, Avelumab, Progression-free survival, MET, SCCHN, Pharmaceutical industry, Nightclub, Merck

Merck, a leading science and technology company, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.

Key Points: 
  • Merck, a leading science and technology company, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.
  • Presentations at the meeting encompass new analyses for the standard-of-care medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab).
  • Additional presentations and activities at ESMO highlight the company’s efforts to improve the lives of people with cancer.
  • New analyses and real-world evidence to be presented at ESMO reinforce the role of the JAVELIN Bladder regimen in this setting.

Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
월요일, 8월 14, 2023
PDAC, Completeness, Rochester, Trastuzumab, Pathology, Merck Group, Cash, Astrocyte, Patient, FCMI, Observation, H. Lee Moffitt Cancer Center & Research Institute, Private placement, Three Months, Eurosport 1, University, Brain, Research, Lecanemab, TME, Motivation, Drug discovery, Neoplasm, FDA, B cell, Safety, Cognition, Neuron, ICI, G protein-coupled receptor, Metastatic breast cancer, DC1, Cancer, Lung cancer, CCR8, Immunotherapy, Antibody, PFS, ARIA, Publication, MBC, Biomarker, Microglia, SEMA4D, Security, ORR, HD, Head and neck cancer, Drug development, Nature, SIGNAL, Avelumab, Neurodegenerative disease, Pfizer, CO, Breast cancer, Pharmaceutical industry, Medical imaging, Vaccine, Cryptocurrency, HNSCC, Merck

ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on progress in key programs. .

Key Points: 
  • Expect to Complete 12-months treatment in June, 2024
    ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on progress in key programs.
  • Over the last few months, Vaccinex achieved several important clinical milestones for pepinemab in both Alzheimer’s disease and Head and Neck Cancer.
  • In the first segment, completed on May 12, 2023, Vaccinex sold approximately 7.9 million shares of common stock for aggregate proceeds of $2.96 million.
  • For further details on Vaccinex’s financials, refer to its Form 10Q filed August 14, 2023 with the S.E.C.

Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Retrieved on: 
월요일, 6월 5, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Antigen, NCT, RECIST, HPV16, Cancer, Trial of the century, E7, ASCO, Euronext Paris, American Society of Clinical Oncology, MD, Patient, E6, Annual general meeting, HPV, Poster, Society, Avelumab, Vaccine, Pharmaceutical industry, Transgene

These data confirm the ability of this novel investigational therapeutic cancer vaccine to induce immune responses against HPV16 antigens, that are associated with anti-tumor response.

Key Points: 
  • These data confirm the ability of this novel investigational therapeutic cancer vaccine to induce immune responses against HPV16 antigens, that are associated with anti-tumor response.
  • These results have been presented in a poster at the ongoing American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
  • These data clearly demonstrate that Transgene’s TG4001 could induce a specific immune response against the antigens vectorized within this vaccine.
  • These data further confirm that our therapeutic vaccine TG4001 can induce clinically meaningful immune responses, that are associated with antitumor response.

Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting

Retrieved on: 
목요일, 5월 25, 2023
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Protein kinase, Safety, European Medicines Agency, PFE, Encorafenib, MEK, CDK, Acquisition, Patient, Bini, Ageing, NYSE, Priority review, Maintenance, Inc., APLS, AUC, ADP, Toxicity, Binimetinib, EMA, Doxorubicin, Medicine, Hematology, TALA, Learning, Abstract, DNA, HRR, Cancer, BRAF, NSCLC, Shanda, BSC, RRMM, PARP, PBO, Abstract (summary), B-cell maturation antigen, Woman, AVE, Clinical Genitourinary Cancer, SHP2, ASCO, American Society of Clinical Oncology, Annual general meeting, RWE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Avelumab, Food, BCMA, Breast cancer, Pharmaceutical industry, Vaccine, Seagen, Pfizer

Pfizer Inc. (NYSE: PFE) will present data across its Oncology portfolio and growing pipeline, covering multiple tumor types and novel mechanisms of action at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2 through June 6.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) will present data across its Oncology portfolio and growing pipeline, covering multiple tumor types and novel mechanisms of action at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2 through June 6.
  • With the recently announced proposed acquisition of Seagen*, a leader in antibody-drug conjugate technology, Pfizer is further accelerating its fight against cancer to deliver the next generation of Oncology breakthroughs.
  • “Placing patients at the center of everything we do is a critical component of advancing cutting-edge science and improving outcomes for patients,” said Dany Habr, M.D., Oncology Chief Medical Affairs Officer, Pfizer.
  • **Pfizer has exclusive rights to BRAFTOVI and MEKTOVI in the U.S., Canada, and all countries in the Latin American, African, and Middle Eastern regions.